UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/576,972	04/25/2006	Wolfgang Froestl	33508-US-PCT	8133	
	5074 7590 02/12/2008 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.			EXAMINER	
400 TECHNOLOGY SQUARE			DAVIS, ZINNA NORTHINGTON		
CAMBRIDGE, MA 02139			ART UNIT	PAPER NUMBER	
			1625		
			MAIL DATE	DELIVERY MODE	
			02/12/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/576,972	FROESTL, WOLFGANG				
Office Action Summary	Examiner	Art Unit				
	Zinna Northington Davis	1625				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
	-· action is non-final.					
<i>i</i> —						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
		0 0.0. 2.0.				
Disposition of Claims						
4) Claim(s) <u>1-7</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-7</u> is/are rejected.						
7) Claim(s) is/are objected to.	·_ · · · · ·					
•	<u> </u>					
,	,					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)⊠ All b)□ Some * c)□ None of:						
1. Certified copies of the priority documents						
<ol><li>Certified copies of the priority documents</li></ol>	2. Certified copies of the priority documents have been received in Application No					
3. ☐ Copies of the certified copies of the prior	ity documents have been receive	d in this National Stage				
application from the International Bureau	application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
3) 🔯 Information Disclosure Statement(s) (PTO/SB/08) 5) 🔲 Notice of Informal Patent Application						
Paper No(s)/Mail Date <u>4/25/06;6/20/06</u> . 6) Other:						

Application/Control Number: 10/576,972 Page 2

Art Unit: 1625

## **DETAILED ACTION**

1. Claims 1-7 are pending.

2. The Preliminary Amendment filed April 25, 2006 has been entered.

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 4. Claims 1-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
  - A. Claims 1 and 4 are identical.
  - B. Claims 2-7 improperly depend upon claim 1. Claim 1 is not claimed in free base form.
- 5. Claim 6 provides for the use of the compound, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.
- 6. Claim 6 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd. App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

The recitation of the term "use" renders the claim non-statutory.

Application/Control Number: 10/576,972 Page 3

Art Unit: 1625

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (b) The invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 8. Claims 1, 3-5, and 7 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Ciba-Geigy AG (Reference AM, cited by Applicant).

The instantly claimed compound is disclosed. At page 8, lines 54-55, see Example 4. The compound is depicted below:

9. Claims 1, 3-5, and 7 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Ciba -Geigy AG (Reference AN, cited by Applicant).

The instantly claimed compound is disclosed. At page 20, see example 10. The compound is depicted below:

- 10. The Information Disclosure Statements filed April 25, 2006 and June 20, 2006 have been considered.
- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna Northington Davis whose telephone number is 571-272-0682.

Application/Control Number: 10/576,972 Page 4

Art Unit: 1625

12. The fax phone number for the organization where this application or proceeding

is assigned is 571-273-8300.

13. Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

/Zinna Northington Davis/
Zinna Northington Davis
Primary Examiner
Art Unit 1625

Znd 02.08. 2008